Skip to main content
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1999 Dec 20;13(6):266–272. doi: 10.1002/(SICI)1098-2825(1999)13:6<266::AID-JCLA3>3.0.CO;2-#

Combination of automatic HPLC‐RIA method for determination of estrone and estradiol in serum

Toshiyuki Yasui 1,, Masayo Yamada 1, Hiromi Kinoshita 1, Hirokazu Uemura 1, Naoto Yoneda 1, Minoru Irahara 1, Toshihiro Aono 1, Satoshi Sunahara 2, Yasuyori Mito 2, Fumihiko Kurimoto 2, Keishi Hata 2
PMCID: PMC6807902  PMID: 10633293

Abstract

We developed a highly sensitive assay for estrone and 17 β‐estradiol in serum. Estrone and 17 β‐estradiol, obtained by solid‐phase extraction using a Sep pak tC18 cartridge, were purified by high‐performance liquid chromatography (HPLC). Quantitation of estrone and 17 β‐estradiol were carried out by radioimmunoassay. Not insignificantly, this automatic system of extraction and HPLC succeeded in analyzing 80 samples a week. Intra‐assay coefficients of variation (CV) for estrone and 17 β‐estradiol ranged from 19.5 to 28.7%, and from 8.5 to 13.7%, respectively. The minimum detectable dose for estrone and 17β‐estradiol were 1.04 pg/ml and 0.64 pg/ml, respectively. The serum levels of 17 β‐estradiol using our method strongly correlated with those by Gas chromatography mass spectrometry (GC‐MS). The serum levels of estrone and 17 β‐estradiol in 154 peri‐ and postmenopausal women were estimated to be between 15 and 27 pg/ml and between 3.5 and 24.0 pg/ml, respectively, while the serum level of 17 β‐estradiol in postmenopausal women, in particular, was estimated to be from 3.5 to 6.3 pg/ml. For postmenopausal women who suffered from vasomotor symptoms, the mean levels of estrone and 17 β‐estradiol at 12 to 18 hours after treatment with daily 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) were 135.0 and 21.3 pg/ml at 12 months, respectively. On the other hand, levels of estrone and 17 β‐estradiol at 12 to 18 hours after treatment with CEE and MPA every other day, were 73.4 and 15.3 pg/ml, respectively. These highly sensitive assays for estrone and 17 β‐estradiol are useful in measuring low levels of estrogen in postmenopausal women, and monitoring estrogen levels in women receiving CEE as hormone replacement therapy. J. Clin. Lab. Anal. 13:266–272, 1999. © 1999 Wiley‐Liss, Inc.

Keywords: estradiol, estrone, HPLC‐RIA, postmenopause

REFERENCES

  • 1. Robertson RD, Picker RH, Wilson PC, Saunders DM. Assessment of ovulation by ultrasound and plasma estradiol determination. Obstet Gynecol 1979;54:686–690. Medline [PubMed] [Google Scholar]
  • 2. Okamoto S, Healy DL, Howlett DT, et al. An analysis of plasma estradiol concentrations during clomiphene citrate‐human menopausal gonadotropin stimulation in vitro fertilization—embryo transfer program. J Clin Endocrinol Metab 1986;63:736–740. Medline [DOI] [PubMed] [Google Scholar]
  • 3. Key TJA, Moore JW. Interference of sex‐hormone binding globulin in a no extraction double antibody radioimmunoassay for estradiol. Clin Chem 1988;34:1357–1358. Medline [PubMed] [Google Scholar]
  • 4. Schloler V, Thode J. Six direct radioimmunoassays of estradiol evaluated. Clin Chem 1988;34:949–52. Medline [PubMed] [Google Scholar]
  • 5. Vasiliades J, Hilgers T, Gentrup B, Remsburg J. Increased estradiol concentration of unknown origin. Clin Chem 1991;37:2152–2153. Medline [PubMed] [Google Scholar]
  • 6. Place VA, Powers M, Darley PE, Schenkel L, Good WR. A double‐blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 1985;152:1092–1099. Medline [DOI] [PubMed] [Google Scholar]
  • 7. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759–763. Medline [PubMed] [Google Scholar]
  • 8. Henderson BE, Ross RK, Paganini‐Hill A, Mack TM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol 1986;154:1181–1186. Medline [DOI] [PubMed] [Google Scholar]
  • 9. Chetkowski RJ, Meldrm DR, Steingold KA, et al. Biological effects of transdermal estradiol. N Engl J Med 1986;314:1615–1620. Medline [DOI] [PubMed] [Google Scholar]
  • 10. Barbieri RL. Hormone treatment of endometriosis: The estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740–745. Medline [DOI] [PubMed] [Google Scholar]
  • 11. Mikhail G, Wu CH, Ferin M, Vande Wiele RL. Radioimmunoassay of plasma estrone and estradiol. Steroids 1970;15:333–352. Medline [DOI] [PubMed] [Google Scholar]
  • 12. Wu CH, Lundy LE. Radioimmunoassay of plasma estrogens. Steroids 1971;18:91–111. Medline [DOI] [PubMed] [Google Scholar]
  • 13. Stoks PG, Benraad TJ. Rapid separation of plasma steroids by reversed‐phase high‐performance liquid chromatography with timed collection of fractions. J Chromatogr 1983;208:408–412. [DOI] [PubMed] [Google Scholar]
  • 14. Imaizumi N, Morimoto S, Kigoshi T, Uchida K, Hosojima H, Yamamoto I. Application of reversed‐phase high‐performance liquid chromatography for radioimmunoassay of plasma 18‐hydroxycorticosterone. J Chromatogr 1984;308:295–300. Medline [DOI] [PubMed] [Google Scholar]
  • 15. Schoneshofer M, Fenner A, Dulce HJ. Assessment of eleven adrenal steroids from a single serum sample by combination of automatic high‐performance liquid chromatography and radioimmunoassay (HPLC‐RIA). J Steroid Biochem 1981;14:377–386. Medline [DOI] [PubMed] [Google Scholar]
  • 16. Ueshiba H, Segawa M, Hayashi T, Miyachi Y, Irie M. Serum profiles of steroid hormones in patients with Cushing's syndrome determined by a new HPLC/RIA method. Clin Chem 1991;37:1329–1333. Medline [PubMed] [Google Scholar]
  • 17. Meldrum DR, Davidson BJ, Tataryn IV, Judd HL. Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 1981;57:624–628. Medline [PubMed] [Google Scholar]
  • 18. Judd HL, Judd GE, Lucas WE, Yen SSC. Endocrine function of the postmenopausal ovary; concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 1974;39:1020–1024. Medline [DOI] [PubMed] [Google Scholar]
  • 19. Judd HL, Shamonski IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982;59:680–686. Medline [PubMed] [Google Scholar]
  • 20. Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low‐dose regimen of estrogen‐progestin for treatment of the menopausal patients. Am J Obstet Gynecol 1990;162:1534–1542. Medline [DOI] [PubMed] [Google Scholar]
  • 21. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. N Engl J Med 1991;325:1189–1195. Medline [DOI] [PubMed] [Google Scholar]
  • 22. Yoneda N, Uemura H, Yasui T, Azuma K, Irahara M, Aono T. Assessment of the efficacy and compliance of the protocol with every other day administration of estrogen and progestin in hormone replacement therapy for women with menopausal symptoms. J Jpn Menopause Soc 1996;4:65–71. [Google Scholar]
  • 23. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Commings SR. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: The study of osteoporotic fractures. J Clin Endocrinol Metab 1998;83:2239–2243. Medline [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES